![Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000253/F1.large.jpg)
Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity | Journal for ImmunoTherapy of Cancer
![Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer | Journal for ImmunoTherapy of Cancer Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/7/1/346/F1.large.jpg)
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer | Journal for ImmunoTherapy of Cancer
![Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/11/e005517/F3.large.jpg)
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer
![Clinicopathological significance of CD47 expression in hepatocellular carcinoma | Journal of Clinical Pathology Clinicopathological significance of CD47 expression in hepatocellular carcinoma | Journal of Clinical Pathology](https://jcp.bmj.com/content/jclinpath/74/2/111/F2.large.jpg)